Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes on May 15, 2027. There are 6 upcoming events on record.
Cash runway is approximately 40.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Track KLRA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KLRA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 20, 2026 | 8-K filed: Other event | Filing | — |
| January 26, 2026 | A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight | Trial Milestone | Phase 1 |
| November 13, 2025 | A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.